SHKP posts another Sierra Sea sell-out as Hong Kong property rebound strengthens


Sun Hung Kai Properties (SHKP), Hong Kong’s largest developer by market capitalisation, sold all 350 units released on Sunday in its Sierra Sea project, marking a fifth consecutive sell-out and underscoring returning buyer appetite in the world’s most expensive property market.

The batch at phase 2B included 244 two-bedroom and 106 three-bedroom units, with discounted prices ranging from HK$4.6 million (US$590,000) to HK$9.74 million, according to sales documents released on Wednesday. The average discounted price came to HK$12,469 per square foot.

The offering followed four sell-outs in January. Phase 2A of the Sai Sha development sold 213 flats on January 10, 229 units on January 17, and 218 homes on January 21. Phase 2B sales opened on January 28 with all 165 price-list units snapped up in about four hours.

More than a fifth of the 9,700 units available have already been sold. Sierra Sea, located at Shap Sze Heung, between Sai Kung and Ma On Shan, is Hong Kong’s largest housing project since 1999. The development featured three themed clubhouses offering 168 amenities, including water play areas, indoor and outdoor sports, cycling trails and themed cabins, according to Centaline Property.

The Sierra Sea project has now recorded five rounds of sold-out flats in 2026. Photo: Jonathan Wong
The Sierra Sea project has now recorded five rounds of sold-out flats in 2026. Photo: Jonathan Wong

The strong sales reflect a property market regaining momentum after multi-year downturns. Lived-in home prices rose 3.25 per cent in 2025, while rents climbed to a record high in December, according to Rating and Valuation Department data.

  • Related Posts

    Stablecoins, wealth platforms launched at Consensus 2026 amid tighter Beijing oversight

    As Consensus 2026 officially kicks off in Hong Kong this week, digital asset firms are rolling out product updates to coincide with one of the industry’s most significant events. Digital…

    Continue reading
    Capital injection: China backs AI drug makers in self-reliance drive

    Hangzhou-based METiS TechBio, founded in 2020, raised 400 million yuan (US$57.9 million) in series D financing in August last year, led by the Beijing Medical and Health Industry Investment Fund…

    Continue reading

    Leave a Reply

    Your email address will not be published. Required fields are marked *